Bringing the fundamentals into focus…
Back to Aurora Cannabis Inc.
How Aurora Cannabis Inc. stacks up
ACB · against 381 other Healthcare companies of similar size
Valuation
30/ 100
Below the middle of the pack.
Ranked #224 of 382 · scores higher than 40% of peers
Bars: peers in each 10-point band of the valuation score42 peers with a valuation score of 30–39, including ACB · Click a bar to see the companies
Why valuation scores 30?
Weighted metrics compared with all Healthcare companies.Mainly because of its EBITDA yield and free cash flow yield, which are weaker than most Healthcare peers.
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. EBITDA yield: -7.9% vs peer median 4.0%
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Free cash flow yield: -11.2% vs peer median 0.0%
- Earnings yield is not reported, so it is left out of the score.
Metric by metric
Position: dot = ACB, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | ACB | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 365 reported | Not reported | -0.3% | — | — | 30% |
| EBITDA yieldHigher is better · 385 reported | -7.9% | 2.0% | 26% | 50% | |
| Free cash flow yieldHigher is better · 190 reported | -11.2% | -9.2% | 44% | 20% | |
| Book yieldHigher is better · 374 reported | 112.1% | 50.9% | 82% | Context only |
A metric that is not reported is left out of the score; the other weights are rescaled.
Ranking by valuation score
Top 5 and the companies ranked around ACBScores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score